APOE-ε4 carriers were reported to have an increased risk of AD (3–15 times) in a gene dose-dependent manner4; these carriers showed different treatment responses to amyloid removal therapy and had more vasogenic edema5, suggesting a different mechanism of action of APOE-ε4 in the pathogenesis of AD. Here, APOE is linked to Alzheimer disease.